Thalidomide-NH-C4-NH2 TFA is primarily utilized in biomedical research, particularly in the development of targeted therapies. It is often employed in the study of protein degradation through the proteolysis-targeting chimera (PROTAC) technology. This compound serves as a key linker or functional group in the design of PROTAC molecules, enabling the selective degradation of disease-causing proteins. Its application extends to cancer research, where it aids in the development of novel treatments by targeting oncoproteins for destruction. Additionally, it is explored in immunology and inflammatory disease studies due to its potential to modulate immune responses and reduce inflammation. Its role in drug discovery highlights its significance in advancing precision medicine.